RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Zimmer Biomet Holdings but lowers the price target from $130 to $120.
October 08, 2024 | 6:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained its Outperform rating on Zimmer Biomet Holdings but has lowered the price target from $130 to $120, indicating a more cautious outlook.
The maintenance of an Outperform rating suggests continued confidence in Zimmer Biomet's performance, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company-specific factors. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100